(Q37881964)

24 August 2017

1 reference

title

Clinical response to statins: mechanism(s) of variable activity and adverse effects (English)

1 reference

24 August 2017

Cesare R Sirtori

1

1 reference

24 August 2017

Giuliana Mombelli

series ordinal

2

1 reference

24 August 2017

Michela Triolo

series ordinal

3

1 reference

24 August 2017

Reijo Laaksonen

series ordinal

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

31 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

44

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

419-432

1 reference

The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Statin-associated myopathy with normal creatine kinase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Pharmacogenomics of statin responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Cholesterol and plant sterol absorption: recent insights

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Impact of apolipoprotein A5 variants on statin treatment efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Association between statin-associated myopathy and skeletal muscle damage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Individualising the risks of statins in men and women in England and Wales: population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Therapeutic effects of ML-236B in primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

3-hydroxy 3-methylglutaryl coenzyme A reductase increase is essential for rat muscle differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Statin safety: lessons from new drug applications for marketed statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

On the mechanisms of statin-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Pharmacogenomics of human OATP transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

The SLCO1B1*5 genetic variant is associated with statin-induced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Direct-to-consumer genome testing: opportunities for pharmacogenomics research?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Transporter pharmacogenetics and statin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

CYP2D6*4 polymorphism is associated with statin-induced muscle effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2011.582135

10.3109/07853890.2011.582135

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference